cfChIP targeting somatic cancer mutations is a promising new methodology for which the basis of liquid biopsies could help understand how expression of mutated oncogenic drivers such as EGFR, ALK, MET and KRAS contribute to carcinogenesis. The gene discussed is EGFR; the disease is cancer.